Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mars van't Veer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Medicine (London, England)|October 5, 2016
Haemophagocytic lymphohistiocytosis: an elusive syndromeWilliam Thomas, Mars Van't Veer, Martin Besser
Transfusion|May 17, 2008
External quality assessment of platelet serology and human platelet antigen genotyping: a 10-year reviewLeendert Porcelijn, Wil van Beers, Jan W Gratama, et al.
Leukemia & Lymphoma|October 3, 2012
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesisFie Juhl Vojdeman, Jesper Jurlander, Mars van't Veer, et al.
Blood|January 14, 2011
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classificationEstella Matutes, Winfried F Pickl, Mars Van't Veer, et al.
Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962Philip M P Poortmans, Hanneke C Kluin-Nelemans, Hanny Haaxma-Reiche, et al.
Blood|July 30, 2005
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factorsDeirdre A Hill, Ethel Gilbert, Graça M Dores, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Medicine (London, England)|October 5, 2016
Haemophagocytic lymphohistiocytosis: an elusive syndromeWilliam Thomas, Mars Van't Veer, Martin Besser
Transfusion|May 17, 2008
External quality assessment of platelet serology and human platelet antigen genotyping: a 10-year reviewLeendert Porcelijn, Wil van Beers, Jan W Gratama, et al.
Leukemia & Lymphoma|October 3, 2012
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesisFie Juhl Vojdeman, Jesper Jurlander, Mars van't Veer, et al.
Blood|January 14, 2011
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classificationEstella Matutes, Winfried F Pickl, Mars Van't Veer, et al.
Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962Philip M P Poortmans, Hanneke C Kluin-Nelemans, Hanny Haaxma-Reiche, et al.
Blood|July 30, 2005
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factorsDeirdre A Hill, Ethel Gilbert, Graça M Dores, et al.
Pageof 1